CASIF.US CASI Pharmaceuticals, Inc.
- Market cap
- USD 2.06M
- P/E
- -
- P/B
- 11.21x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CASIF.US undervalued?
Graham numberThe Graham number of CASI Pharmaceuticals, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CASI Pharmaceuticals, Inc. fundamental analysis
No fundamental analysis for CASI Pharmaceuticals, Inc. yet.
CASI Pharmaceuticals, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, a Melphalan injection for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company also develops CNCT19, an autologous CD19 CAR-T investigative product for the treatment o…
Full company profileCASI Pharmaceuticals, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CASI Pharmaceuticals, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 4.13M | 15.1M | 30.2M | 43.1M | 33.9M | 28.5M | 20.7M | 19.6M |
| Gross Profit | -66.5K | -118K | -1.67M | 196K | 5.63M | 17.6M | 27.3M | 20.1M | 11.1M | 10.1M | 15.3M |
| Operating Income | 9.42M | -10.8M | -26.5M | -40.0M | -52.8M | -41.5M | -26.5M | -25.1M | -39.6M | -42.8M | -32.2M |
| EBITDA | -9.35M | -10.6M | -25.8M | -37.4M | -31.4M | -33.4M | -35.8M | -21.5M | -34.9M | -43.8M | -31.6M |
| Net Income | -9.45M | -10.8M | -27.5M | -45.4M | -48.3M | -36.7M | -41.0M | -26.9M | -39.3M | -48.1M | -40.1M |
| EPS | -1.69 | -1.75 | -3.24 | -4.73 | -4.37 | -2.69 | -3.01 | -2.02 | -2.56 | -2.59 | -1.95 |
| Balance Sheet | |||||||||||
| Total Assets | 27.7M | 45.1M | 113M | 103M | 128M | 138M | 96.2M | 75.3M | 53.7M | 25.7M | 21.1M |
| Total Liabilities | 6.93M | 6.56M | 3.95M | 8.97M | 24.2M | 30.3M | 29.3M | 51.1M | 51.8M | 62.9M | 79.3M |
| Shareholders' Equity | 20.8M | 38.5M | 109M | 73.0M | 81.5M | 84.5M | 44.6M | 24.2M | 1.85M | -37.3M | -58.3M |
| Cash & Short-term Investments | 27.1M | 43.5M | 85.1M | 54.2M | 66.4M | 48.6M | 51.3M | 30.8M | 16.1M | 5.63M | 3.77M |
| Total Debt | 1.49M | 1.50M | 1.50M | 2.20M | 3.20M | 4.33M | 1.34M | 21.2M | 22.1M | 27.5M | 40.5M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.02M | -6.40M | -28.6M | -23.2M | -25.9M | -26.8M | -21.1M | -20.0M | -29.2M | -20.8M | - |
| Capital Expenditure | 223K | 935K | 21.8M | 14.0M | 19.3M | 15.5M | 5.61M | 2.24M | 240K | 16.0K | 0.00 |
| Free Cash Flow | -6.25M | -7.34M | -50.4M | -37.3M | -45.2M | -42.3M | -26.7M | -22.2M | -29.5M | -20.8M | - |
| Ratios | |||||||||||
| ROE | -45.5% | -27.9% | -25.1% | -62.1% | -59.2% | -43.4% | -92.0% | -111.5% | -2,120.9% | - | - |
| ROA | -34.1% | -23.9% | -24.2% | -44.2% | -37.8% | -26.5% | -42.6% | -35.8% | -73.1% | -187.4% | -190.2% |
| Net Profit Margin | - | - | - | -1,098.1% | -318.9% | -121.5% | -95.1% | -79.5% | -137.6% | -232.0% | -204.1% |
| Debt to Equity | 0.07x | 0.04x | 0.01x | 0.03x | 0.04x | 0.05x | 0.03x | 0.88x | 11.96x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CASI Pharmaceuticals, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | USD 718K | 0.05 | - |
| 2023 | USD 738K | 0.06 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Jun 2, 2022.
Who owns CASI Pharmaceuticals, Inc.
- Insiders 45.47%
- Institutions 26.49%
- Public & others 28.04%
- Shares outstanding 20.6M
- Free float 9.72M
CASI Pharmaceuticals, Inc. company profile
- Company name
- CASI Pharmaceuticals, Inc.
- Ticker
- CASIF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 214
- Fiscal year end
- December
- Address
- 1701-1702, China Central Office Tower 1, Beijing, China, 100025
- Phone
- 86 10 6508 6063
- Website
- casipharmaceuticals.com
About CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, a Melphalan injection for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company also develops CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with hematological malignancies; BI-1206, an novel anti-Fc"RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody for the treatment of patients with multiple myeloma; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
CASI Pharmaceuticals, Inc. management
6- Dr. Wei-Wu He Ph.D.Executive Chairman of the Board & Principal Executive Officer · born 1965
- Ms. Kun QianVP & Global Controller · born 1982
- Ms. Chunhua WangChief Operating Officer · born 1972
- Ms. Wei GaoGeneral Counsel · born 1982
- Mr. Hai HuangChief Commercial Officer & GM · born 1969
- Dr. Junping Chen M.D., Ph.D.Senior VP of Medical of US & Chief Medical Officer of China